How will AMYPAD help clinical trials?

The AMYPAD PNHS study will help improve the understanding of disease pathophysiology. Also it will gather information about research participants, notably about the presence of biomarkers for Alzheimer’s disease, which can be used to select research participants for clinical trials. Also, it makes the inclusion of research participants in clinical trials more efficient: participants from EPAD or other non-EPAD cohorts have the advantage of being already well-characterized both by the assessments made in EPAD LCS or non-EPAD cohorts and in AMYPAD PNHS. This prevents the undue inclusion in Alzheimer’s dementia prevention trials of people who are unlikely to develop Alzheimer’s dementia.